FindTrial
Sign In

STK-009

DRUG2 trials

Sponsors

Synthekine

Conditions

CLL/SLLDiffuse Large B Cell LymphomaFollicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaLarge B-cell LymphomaLupus NephritisMantle Cell LymphomaNHL

Phase 1

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Active, not recruitingNCT05665062
SynthekineCLL/SLL, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +4
Start: 2023-04-23End: 2041-11-01Target: 36Updated: 2026-07-10
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
Active, not recruitingNCT06544330
SynthekineLupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis
Start: 2025-04-29End: 2041-04-01Target: 48Updated: 2026-07-10

Related Papers

Abstract 6312: Orthogonal IL-2/IL-2Rβ signaling selectively enhances and sustains a synthetic effector state via a novel mechanism and outperforms constitutive armoring approaches
Cancer Research2024-03-22
228 Engineered human IL-2/IL-2Rß orthogonal pairs selectively enhance anti-GPC3 CAR T cells in vivo to drive complete responses in solid epithelial tumor models
Regular and Young Investigator Award Abstracts2023-10-311 citations
Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory  CD19 expressing hematologic malignancies (NCT05665062)
Cancer Research2023-04-143 citations